IMMUPHARMA PLC – Corporate Update

20 March 2026

ImmuPharma PLC (IMM@AIM) provided an investor update outlining its strategic funding decision, pipeline progress, and growth strategy, reaffirming that its lead asset P140 remains the core value driver with ongoing licensing discussions and strong scientific validation supporting potential deals in 2026. The company highlighted continued progress on patents, expanded indications across autoimmune diseases, and confidence in future revenue potential. Alongside this, ImmuPharma announced new funding to accelerate development of Kapiglucagon, a novel prodrug targeting the growing type 1 diabetes market, with a fast track regulatory pathway and expected commercialization timeline of around two years. Management emphasized that the fundraising strengthens the broader portfolio without detracting from P140, aiming to enhance long term shareholder value despite dilution. The company expects strong news flow, potential partnership opportunities, and significant market potential, with Kapiglucagon projected to access a multibillion dollar market and deliver meaningful revenue growth. Overall, the update underscores improving company performance, a diversified pipeline, and a clear focus on value creation through disciplined capital allocation and strategic execution.. – March 2026

ImmuPharma CEO on P140 progress and expanded pipeline with Kapiglucagon

17 March 2026

ImmuPharma PLC (AIM:IMM, FRA:25I) CEO Tim McCarthy joined Stephen Gunnion in the Proactive studio to discuss the company’s latest developments, including progress on its lead asset P140, a newly accelerated program for Kapiglucagon, and recent fundraising activity. – March 2026

ImmuPharma CEO confident on P140 partnership as strong pharma interest extends timeline into 2026

28 November 2025

ImmuPharma PLC (AIM:IMM) CEO Tim McCarthy talked with Proactive’s Stephen Gunnion about the company’s ongoing discussions to secure a partnership for its lead asset, P140 – November 2025

Midweek Takeaway featuring Tim McCarthy, CEO of ImmuPharma

26 November 2025

In this episode of The Midweek Takeaway, Phil Carroll and Kevin Hornsby are joined by Tim McCarthy, CEO of ImmuPharma, for an in-depth update on the company’s P140 autoimmune platform. – November 2025

“Putting Patients into Remission”: ImmuPharma’s Autoimmune Breakthrough with P140

16 September 2025

CEO, Tim McCarthy joins Stockhouse – “Putting Patients into Remission”: ImmuPharma’s Autoimmune Breakthrough with P140

Zak Mir talks to Tim McCarthy, CEO Immupharma

12 September 2025

Zak Mir talks to Tim McCarthy, CEO Immupharma, in the wake of the specialty biopharmaceutical company that discovers and develops peptide-based therapeutics, announcing the filing of a groundbreaking new patent application for its lead asset P140, the world’s first “Immunormalizer.”

Midweek Takeaway – Tim McCarthy, CEO,& Dr Sébastien Goudreau, newly appointed CSO of ImmuPharma

5 September 2025

Tim McCarthy, CEO, and Dr Sébastien Goudreau, CSO, joins Sunday Roast Podcast to discuss a groundbreaking patent for its lead asset P140, the world’s first “Immunormalizer,” – September 2025

ImmuPharma CEO & CSO on major patent milestone for P140 autoimmune therapy

2 September 2025

ImmuPharma’s CEO Tim McCarthy and CSO Dr Sébastien Goudreau talk with Proactive Investor about the Company’s latest milestone — the filing of a new patent application for its lead autoimmune drug therapy, P140, described as the world’s first “immunormaliser’ – September 2025

Zak Mir talks to Tim McCarthy, CEO ImmuPharma, in the wake of a series of announcements this year which have transformed the outlook for the AIM listed (LSE:IMM) evolving speciality pharma company.

17 March 2025

Tim McCarthy, CEO of ImmuPharma talks to Zak MIr at ‘Traders Cafe’ focusing on the UK biotech arena as a public company together with two key significant scientific announcements issued by ImmuPharma over the last period, including more details on the MOA of IMMs auto-immune technology platform, P140 – March 2025

Sunday Roast-Tim, CEO #IMM

16 March 2025

ImmuPharma’s CEO, Tim McCarthy talks again to Sunday Roast investment podcast, to give detail on the recent announcement on the mechanism of action of IMMs autoimmune P140 technology and how important this is in current and future business development discussions – March 2025

ImmuPharma CEO on oversubscribed fundraising and strong 2025 outlook

January 2025

Tim McCarthy, CEO of ImmuPharma talks to Proactive Investor about the recent oversubscribed fundraising and strong outlook for 2025 – February 2025

Sunday Roast featuring Tim McCarthy, CEO of ImmuPharma

January 2025

Tim McCarthy, CEO of ImmuPharma, joins Sunday Roast podcast to discuss how the company is revolutionizing healthcare with peptide-based therapies – Jan 2025

Proactive – ImmuPharma “looking forward” to upcoming FDA meetings

January 2025

ImmuPharma’s CEO Tim McCarthy shares latest developments with P140 platform and exciting road ahead with business development over 2025 – January 2025

Proactive – ImmuPharma discusses financial stability and promising drug developments

6 March 2024

ImmuPharma CEO Tim McCarthy discusses financial stability and promising drug developments – 6 March 2024

Zak Mir – Tim McCarthy, CEO Immupharma

22 September 2023

Zak Mir talks to Tim McCarthy, Chairman and CEO, Immupharma, about the recent fund raise, highlights of the company’s portfolio, and the main focus of its drug discovery and development strategy – 22 September 2023

Proactive – ImmuPharma “delighted” to push on with new clinical trial

28 June 2023

ImmuPharma “absolutely delighted” to push on with new clinical trial.

Proactive – ImmuPharma “looking forward” with quiet confidence” to FDA response

24 May 2023

Tim McCarthy, CEO of ImmuPharma talks to Proactive Investors on the recent positive guidance from the FDA on its autoimmune program, CIDP – 24 May 2023

Proactive – ImmuPharma “looking forward” to upcoming FDA meetings

27 April 2023

Tim McCarthy, CEO talks to Proactive on recent positive newsflow and his optimism on the forthcoming FDA meetings for Lupuzor for lupus and CIDP – 27 April 2023